UniQure CEO Soland makes a quick ex­it as ex­ecs ham­mer out a new strat­e­gy

Nine months af­ter land­ing a new job as CEO of the Dutch gene ther­a­py biotech uniQure, Dan Soland abrupt­ly quit on Thurs­day, say­ing the un­ex­pect­ed move was due “sole­ly” to fam­i­ly rea­sons. And the com­pa­ny says it doesn’t plan on re­plac­ing him im­me­di­ate­ly, pre­fer­ring to wait un­til af­ter it im­ple­ments a new cor­po­rate strat­e­gy now in the works.

CFO Matthew Ka­pus­ta will now take the helm as in­ter­im CEO, with for­mer pres­i­dent Philip Ast­ley-Sparke step­ping up as chair­man. In a state­ment, Ast­ley-Sparke praised Ka­pus­ta for his work “guid­ing an on­go­ing, com­pre­hen­sive strate­gic plan­ning process.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER